Seasonal influenza virus vaccine quadrivalent - sanofi pasteur

Drug Profile

Seasonal influenza virus vaccine quadrivalent - sanofi pasteur

Alternative Names: Fluzone QIV ID; Fluzone QIV IM; Fluzone Quadrivalent; Fluzone Quadrivalent vaccine; QIV; Quadrivalent inactivated influenza virus vaccine; Quadrivalent influenza vaccine; Vaxigrip QIV IM; VaxigripTetra

Latest Information Update: 06 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator sanofi pasteur
  • Developer Sanofi Pasteur
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 28 Jan 2017 Sanofi Pasteur completes a phase III trial in Influenza virus infections (Prevention, Prevention, In infants, In children, In adolescents, In adults, In the elderly) in India (IM) (NCT02451358)
  • 02 Jan 2017 Sanofi Pasteur MSD ended their joint venture and will separately pursue their vaccine strategies in Europe
  • 01 Jul 2016 Sanofi Pasteur completes a phase-III trial in Influenza virus infections (In adults, Prevention) in South Korea (IM) (NCT02550197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top